Use of 3′-Deoxy-3′-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-hodgkin's lymphoma

Jessica Lawrence, Matthew Vanderhoek, David Barbee, Robert Jeraj, Daniel B. Tumas, David M. Vail

Research output: Contribution to journalArticle

  • 28 Citations

Abstract

Imaging and measurement of proliferation with computed tomography (CT) and positron emission tomography (PET) provide a noninvasive method for improved staging and monitoring of response to cancer treatment. We evaluated prospectively the proliferation marker 3′-deoxy-3′[18F] fluorothymidine (FLT) in the context of FLT-PET/CT for detection of early response, confirmation of posttreatment response, and prediction of relapse in dogs with non-Hodgkin's lymphoma. Nine dogs with non-Hodgkin's lymphoma who were scheduled to receive five cycles of an investigational cytotoxic chemotherapy agent were included. All dogs received baseline FLT-PET/CT imaging immediately before chemotherapy. Intent was to repeat imaging with FLT-PET/CT at various time points: group 1 (n=4), 5 days after initiation of chemotherapy and 3 weeks following the last chemotherapy administration; group 2 (n=5), before the fourth cycle of chemotherapy and 3 weeks following the last administration. Two dogs in group 2 did not undergo repeat PET/CT. Body mass standardized uptake values (SUV) for FLT were calculated for each dog. Eight dogs had initially increased FLT uptake (mean SUVmax=9.8 [2.6-22.3]). Mean SUV decreased significantly for the seven dogs that underwent follow-up PET/CT following chemotherapy (mean SUVmax=3.5 [1.1-7.9], P<0.016). Increased uptake preceded clinical and cytological evidence of relapse in two dogs. Ki-67 immunohistochemistry confirmed decreased proliferation corresponding to decreased SUV in three canine lymph node samples. FLT-PET/CT functional and anatomical imaging shows promise for the evaluation of response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma and for predicting relapse before standard clinical and clinicopathologic confirmation.

LanguageEnglish (US)
Pages660-668
Number of pages9
JournalVeterinary Radiology and Ultrasound
Volume50
Issue number6
DOIs
StatePublished - Nov 1 2009

Fingerprint

non-Hodgkin lymphoma
positron-emission tomography
computed tomography
Non-Hodgkin's Lymphoma
drug therapy
Dogs
Drug Therapy
dogs
relapse
image analysis
Recurrence
Positron Emission Tomography Computed Tomography
Cytotoxins
Canidae
immunohistochemistry
lymph nodes
Lymph Nodes
Immunohistochemistry

Keywords

  • 3′-deoxy-3′[18F] fluorothymidine
  • Canine
  • Non-Hodgkin's lymphoma
  • Positron emission tomography

Cite this

Use of 3′-Deoxy-3′-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-hodgkin's lymphoma. / Lawrence, Jessica; Vanderhoek, Matthew; Barbee, David; Jeraj, Robert; Tumas, Daniel B.; Vail, David M.

In: Veterinary Radiology and Ultrasound, Vol. 50, No. 6, 01.11.2009, p. 660-668.

Research output: Contribution to journalArticle

Lawrence, Jessica ; Vanderhoek, Matthew ; Barbee, David ; Jeraj, Robert ; Tumas, Daniel B. ; Vail, David M./ Use of 3′-Deoxy-3′-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-hodgkin's lymphoma. In: Veterinary Radiology and Ultrasound. 2009 ; Vol. 50, No. 6. pp. 660-668
@article{f31248db6c794410ac0062f0aede792e,
title = "Use of 3′-Deoxy-3′-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-hodgkin's lymphoma",
abstract = "Imaging and measurement of proliferation with computed tomography (CT) and positron emission tomography (PET) provide a noninvasive method for improved staging and monitoring of response to cancer treatment. We evaluated prospectively the proliferation marker 3′-deoxy-3′[18F] fluorothymidine (FLT) in the context of FLT-PET/CT for detection of early response, confirmation of posttreatment response, and prediction of relapse in dogs with non-Hodgkin's lymphoma. Nine dogs with non-Hodgkin's lymphoma who were scheduled to receive five cycles of an investigational cytotoxic chemotherapy agent were included. All dogs received baseline FLT-PET/CT imaging immediately before chemotherapy. Intent was to repeat imaging with FLT-PET/CT at various time points: group 1 (n=4), 5 days after initiation of chemotherapy and 3 weeks following the last chemotherapy administration; group 2 (n=5), before the fourth cycle of chemotherapy and 3 weeks following the last administration. Two dogs in group 2 did not undergo repeat PET/CT. Body mass standardized uptake values (SUV) for FLT were calculated for each dog. Eight dogs had initially increased FLT uptake (mean SUVmax=9.8 [2.6-22.3]). Mean SUV decreased significantly for the seven dogs that underwent follow-up PET/CT following chemotherapy (mean SUVmax=3.5 [1.1-7.9], P<0.016). Increased uptake preceded clinical and cytological evidence of relapse in two dogs. Ki-67 immunohistochemistry confirmed decreased proliferation corresponding to decreased SUV in three canine lymph node samples. FLT-PET/CT functional and anatomical imaging shows promise for the evaluation of response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma and for predicting relapse before standard clinical and clinicopathologic confirmation.",
keywords = "3′-deoxy-3′[18F] fluorothymidine, Canine, Non-Hodgkin's lymphoma, Positron emission tomography",
author = "Jessica Lawrence and Matthew Vanderhoek and David Barbee and Robert Jeraj and Tumas, {Daniel B.} and Vail, {David M.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1111/j.1740-8261.2009.01612.x",
language = "English (US)",
volume = "50",
pages = "660--668",
journal = "Veterinary Radiology and Ultrasound",
issn = "1058-8183",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Use of 3′-Deoxy-3′-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-hodgkin's lymphoma

AU - Lawrence,Jessica

AU - Vanderhoek,Matthew

AU - Barbee,David

AU - Jeraj,Robert

AU - Tumas,Daniel B.

AU - Vail,David M.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Imaging and measurement of proliferation with computed tomography (CT) and positron emission tomography (PET) provide a noninvasive method for improved staging and monitoring of response to cancer treatment. We evaluated prospectively the proliferation marker 3′-deoxy-3′[18F] fluorothymidine (FLT) in the context of FLT-PET/CT for detection of early response, confirmation of posttreatment response, and prediction of relapse in dogs with non-Hodgkin's lymphoma. Nine dogs with non-Hodgkin's lymphoma who were scheduled to receive five cycles of an investigational cytotoxic chemotherapy agent were included. All dogs received baseline FLT-PET/CT imaging immediately before chemotherapy. Intent was to repeat imaging with FLT-PET/CT at various time points: group 1 (n=4), 5 days after initiation of chemotherapy and 3 weeks following the last chemotherapy administration; group 2 (n=5), before the fourth cycle of chemotherapy and 3 weeks following the last administration. Two dogs in group 2 did not undergo repeat PET/CT. Body mass standardized uptake values (SUV) for FLT were calculated for each dog. Eight dogs had initially increased FLT uptake (mean SUVmax=9.8 [2.6-22.3]). Mean SUV decreased significantly for the seven dogs that underwent follow-up PET/CT following chemotherapy (mean SUVmax=3.5 [1.1-7.9], P<0.016). Increased uptake preceded clinical and cytological evidence of relapse in two dogs. Ki-67 immunohistochemistry confirmed decreased proliferation corresponding to decreased SUV in three canine lymph node samples. FLT-PET/CT functional and anatomical imaging shows promise for the evaluation of response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma and for predicting relapse before standard clinical and clinicopathologic confirmation.

AB - Imaging and measurement of proliferation with computed tomography (CT) and positron emission tomography (PET) provide a noninvasive method for improved staging and monitoring of response to cancer treatment. We evaluated prospectively the proliferation marker 3′-deoxy-3′[18F] fluorothymidine (FLT) in the context of FLT-PET/CT for detection of early response, confirmation of posttreatment response, and prediction of relapse in dogs with non-Hodgkin's lymphoma. Nine dogs with non-Hodgkin's lymphoma who were scheduled to receive five cycles of an investigational cytotoxic chemotherapy agent were included. All dogs received baseline FLT-PET/CT imaging immediately before chemotherapy. Intent was to repeat imaging with FLT-PET/CT at various time points: group 1 (n=4), 5 days after initiation of chemotherapy and 3 weeks following the last chemotherapy administration; group 2 (n=5), before the fourth cycle of chemotherapy and 3 weeks following the last administration. Two dogs in group 2 did not undergo repeat PET/CT. Body mass standardized uptake values (SUV) for FLT were calculated for each dog. Eight dogs had initially increased FLT uptake (mean SUVmax=9.8 [2.6-22.3]). Mean SUV decreased significantly for the seven dogs that underwent follow-up PET/CT following chemotherapy (mean SUVmax=3.5 [1.1-7.9], P<0.016). Increased uptake preceded clinical and cytological evidence of relapse in two dogs. Ki-67 immunohistochemistry confirmed decreased proliferation corresponding to decreased SUV in three canine lymph node samples. FLT-PET/CT functional and anatomical imaging shows promise for the evaluation of response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma and for predicting relapse before standard clinical and clinicopathologic confirmation.

KW - 3′-deoxy-3′[18F] fluorothymidine

KW - Canine

KW - Non-Hodgkin's lymphoma

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=70350508198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350508198&partnerID=8YFLogxK

U2 - 10.1111/j.1740-8261.2009.01612.x

DO - 10.1111/j.1740-8261.2009.01612.x

M3 - Article

VL - 50

SP - 660

EP - 668

JO - Veterinary Radiology and Ultrasound

T2 - Veterinary Radiology and Ultrasound

JF - Veterinary Radiology and Ultrasound

SN - 1058-8183

IS - 6

ER -